Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells
Status
Conditions
Treatments
Details and patient eligibility
About
Recently the general medical literature has become aware that the use of certain long-acting insulin analogues could potentially increase cancer risk.During the last few years the investigators group generated information of both scientific and clinical relevance on the proliferative and anti-apoptotic actions of insulin analogues. The goal of this project is to evaluate the hypothesis that the proliferative and signalling activities elicited by insulin analogues may have a impact on tumor behavior. In this study the investigators will asses the biological actions of insulin analogs in primary tumor cells of endometrial and colon cancer.
Sex
Ages
Volunteers
Inclusion criteria
- Patients with Endometrial and Colon Cancer
Exclusion criteria
- None
Trial contacts and locations
Loading...
Central trial contact
Ilan Bruchim, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal